Physician profile
John C Hackenberg
NPI 1083603245
$1,363.71
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2021: $606 · 2022: $517.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $457.75 | 2019-2022 | |
| Abbott Laboratories | $195.98 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $152.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $143.41 | 2019-2022 | |
| Dexcom, INC. | $101.55 | 2021 | |
| Merck Sharp & Dohme LLC | $82.44 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.35 | 2021-2022 | |
| Optinose US, INC. | $47.52 | 2021-2022 | |
| Lilly USA, LLC | $45.60 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $22.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.48 | 2019 | |
| Abbvie INC. | $12.18 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hackenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.